Immediate Impact

55 standout
Sub-graph 1 of 22

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
2025 Standout
1 intermediate paper

Works of Adèle Coriati being referenced

Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada
2021
Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis
2019

Author Peers

Author Last Decade Papers Cites
Adèle Coriati 448 84 195 225 39 661
Michael S. Stalvey 426 50 151 126 32 704
Tamarah Katz 538 61 54 173 34 790
Daniel B. Caplan 352 42 55 104 29 769
Yvonne Belessis 477 43 42 139 28 586
Michael J. Coffey 284 12 50 293 41 711
Oppenheimer Eh 357 27 33 219 26 667
Eggert Lilienthal 104 28 534 399 34 782
Takahisa Kimata 159 41 24 151 56 771
Ross F. Goldberg 142 38 89 302 25 602
Hume Dm 221 68 43 292 53 722

All Works

Loading papers...

Rankless by CCL
2026